Radiopharm Theranostics Files 6-K for August 2025
Ticker: RDPTF · Form: 6-K · Filed: Aug 29, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, sec-filing
TL;DR
Radiopharm Theranostics filed a 6-K for August 2025, confirming 20-F annual report filings.
AI Summary
Radiopharm Theranostics Limited filed a Form 6-K on August 29, 2025, reporting information for the month of August 2025. The company, based in Carlton South, Victoria, Australia, is a foreign private issuer and files under the 1934 Act. This filing indicates they will file annual reports under cover of Form 20-F.
Why It Matters
This filing provides routine updates for investors and regulators regarding Radiopharm Theranostics' ongoing reporting obligations as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain significant new financial or operational information.
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- August 2025 (date) — Reporting period
- Carlton South, Victoria, Australia (location) — Principal executive office
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report cover
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer for the month of August 2025, providing information to the SEC.
Where is Radiopharm Theranostics Limited's principal executive office located?
The principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Does Radiopharm Theranostics Limited file annual reports under Form 20-F or Form 40-F?
The company indicates it files annual reports under cover of Form 20-F.
What is the Commission File Number for Radiopharm Theranostics Limited?
The Commission File Number is 001-41621.
Is Radiopharm Theranostics Limited furnishing information under Rule 12g3-2(b)?
No, the company has marked 'No' for furnishing information under Rule 12g3-2(b).
Filing Stats: 316 words · 1 min read · ~1 pages · Grade level 19.1 · Accepted 2025-08-29 08:34:49
Filing Documents
- ea0255218-6k_radio.htm (6-K) — 13KB
- ea025521801ex99-1_radio.htm (EX-99.1) — 295KB
- ex99-1_001.jpg (GRAPHIC) — 624KB
- ex99-1_002.jpg (GRAPHIC) — 583KB
- ex99-1_003.jpg (GRAPHIC) — 5KB
- 0001213900-25-082105.txt ( ) — 1979KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on August 29, 2025 titled: - “Appendix 4E and Preliminary Final Report” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Appendix 4E and Preliminary Final Report 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: August 29, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3